Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:41:17.801Z.
Calculation as of: 2026-10-06T19:41:17.801Z.
Quote observation: 2026-10-06T19:40:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f06204e81c8a2ed41a5798160e844c591f5150b644efe168084329023db9ebc4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
DiaMedica Therapeutics Inc.
Market Cap
$439.31M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$439.55M
Price/FCF Ratio
N/A
TTM Avg
3.58
3Y Avg
3.58
5Y Avg
3.58
Market Cap
$446.85M
Price/FCF Ratio
N/A
TTM Avg
1.92
3Y Avg
1.92
5Y Avg
1.92
Market Cap
$449.45M
Price/FCF Ratio
N/A
TTM Avg
27.83
3Y Avg
27.83
5Y Avg
27.83
Market Cap
$423.92M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | $439.31M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | N/A | 3.58 | 3.58 | 3.58 |
| NeuroPace, Inc. (NPCE)vs › | $435.72M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $446.85M | N/A | 1.92 | 1.92 | 1.92 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $449.45M | N/A | 27.83 | 27.83 | 27.83 |
| NeoGenomics, Inc. (NEO)vs › | $428.08M | N/A | 53.25 | 37.33 | 28.89 |
| NRC Health (NRC)vs › | $454.11M | 20.98 | 27.39 | 28.55 | 30.18 |
| Tectonic Therapeutic, Inc. (TECX)vs › | $423.92M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $424.40M | N/A | N/A | N/A | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $422.75M | N/A | 102.37 | 102.37 | 102.37 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
